


**Amendments to the Claims**

This listing of the claims will replace all prior versions and listing of claims in this application.

**Listing of Claims**

1. (Currently Amended) A solid pharmaceutical formulation comprising:
  - a. an active pharmaceutical ingredient which is a quinolone antibiotic,
  - b. 4 to 20 % by weight of a flavoring which is a mixture of proteins, fats, and carbohydrates, and,
  - c. 1.5% to 15% by weight of colloidal silicon dioxide based on the total weight of the finished formulation wherein the ratio by weight of colloidal silicon dioxide to flavoring is 1:4 to 1:1, **and wherein the formulation excludes starch.**
2. (Previously Presented) The solid pharmaceutical formulation according to claim 1, wherein the quinolone antibiotic is selected from the group consisting of enrofloxacin, an enrofloxacin salt or a hydrate of enrofloxacin or of its salt.
3. (Previously Presented) The solid pharmaceutical formulation according to claim 1, wherein the quinolone antibiotic is selected from the group consisting of pradofloxacin, a pradofloxacin salt or a hydrate of pradofloxacin or of its salt.
4. (Previously Presented) A process for producing the solid pharmaceutical formulation according to claim 1, in which the flavoring is granulated with the colloidal silicon dioxide and with one or more active ingredients and pharmaceutically customary additives and/or excipients.
5. (Previously Presented) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (I)




(I)

in which

A is nitrogen or =C-R<sup>4</sup>,

R<sup>4</sup> is hydrogen, fluorine, chlorine, cyano, nitro or methyl,

B is



and

R<sup>5</sup> is hydrogen, a branched or unbranched alkyl group having 1 to 4 carbon atoms, which may optionally be substituted by a hydroxyl or methoxy group,

R<sup>6</sup> is hydrogen, methyl or phenyl,

R<sup>7</sup> is hydrogen or methyl,

R<sup>8</sup> is amino, alkyl- or dialkylamino having 1 or 2 carbon atoms in the alkyl group, aminomethyl, alkyl- or dialkylaminomethyl having 1 or 2 carbon atoms in the alkyl group,


R<sup>1</sup> is an alkyl radical having 1 to 3 carbon atoms, cyclopropyl, 2-fluoroethyl, vinyl, methoxy, 4-fluorophenyl or methylamino,

R<sup>2</sup> is hydrogen, alkyl having 1 to 6 carbon atoms, and cyclohexyl, benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl, and

Z is oxygen, methyl- or phenyl-substituted nitrogen, and -CH<sub>2</sub>-,


or a pharmaceutically usable salt thereof.

6. (Withdrawn) A solid pharmaceutical formulation according to Claim 1,  
comprising a quinolone antibiotic of formula (II)



in which

B is



and

R<sup>5</sup> is hydrogen, a branched or unbranched alkyl group having 1 to 4 carbon atoms, which may optionally be substituted by a hydroxyl or methoxy group,

R<sup>6</sup> is hydrogen, methyl or phenyl,

R<sup>7</sup> is hydrogen or methyl,

R<sup>8</sup> is amino, alkyl- or dialkylamino having 1 or 2 carbon atoms in the alkyl group, aminomethyl, alkyl- or dialkylaminomethyl having 1 or 2 carbon atoms in the alkyl group,


R<sup>2</sup> is hydrogen, alkyl having 1 to 6 carbon atoms, and cyclohexyl, benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl,

R<sup>3</sup> is hydrogen, methyl or ethyl, and

Z is oxygen, methyl- or phenyl-substituted nitrogen, and -CH<sub>2</sub>-,


or a pharmaceutically usable salt thereof.

7. (Previously Presented) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (Ia)



in which

B is



and

A is nitrogen or =C-R⁴,

R⁴ is hydrogen, fluorine, chlorine, cyano, nitro or methyl,

R⁵ is hydrogen, a branched or unbranched alkyl group having 1 to 4 carbon atoms, which may optionally be substituted by a hydroxyl or methoxy group,


R⁶ is hydrogen, methyl or phenyl,

R⁷ is hydrogen or methyl, and

R² is hydrogen, alkyl having 1 to 6 carbon atoms, and cyclohexyl, benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl,

or a pharmaceutically usable salt thereof.


8. (Previously Presented) A solid pharmaceutical formulation according to Claim 1, comprising a quinolone antibiotic of formula (Ia)



in which

R<sup>2</sup> is hydrogen, alkyl having 1 to 4 carbon atoms, and benzyl, 2-oxopropyl, phenacyl and ethoxycarbonylmethyl,

B is



R<sup>5</sup> is hydrogen, methyl or ethyl,

R<sup>6</sup> is hydrogen or methyl,

R<sup>7</sup> is hydrogen or methyl,

A is nitrogen or =C-R<sup>4</sup>, and

R<sup>4</sup> is hydrogen, fluorine, chlorine, cyano, nitro or methyl,  
or a pharmaceutically usable salt thereof.

9. (Previously Presented) The solid pharmaceutical formulation according to claim 1, comprising at least 2.5% by weight silicon dioxide.

10. (Previously Presented) The solid pharmaceutical formulation according to claim 1, comprising not more than 15% by weight of silicon dioxide.